CA3164226A1 - Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof - Google Patents

Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof

Info

Publication number
CA3164226A1
CA3164226A1 CA3164226A CA3164226A CA3164226A1 CA 3164226 A1 CA3164226 A1 CA 3164226A1 CA 3164226 A CA3164226 A CA 3164226A CA 3164226 A CA3164226 A CA 3164226A CA 3164226 A1 CA3164226 A1 CA 3164226A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
acid sequence
identity
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3164226A
Other languages
English (en)
French (fr)
Inventor
Matthew Lorenzi
Sylvie Laquerre
Simon Brack
Kristina KLUPSCH
Babette SCHADE
Vanessa BAERISWYL
Michela Silacci Melkko
Julian Bertschinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cilag GmbH International
Original Assignee
Cilag GmbH International
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cilag GmbH International filed Critical Cilag GmbH International
Publication of CA3164226A1 publication Critical patent/CA3164226A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3164226A 2019-12-11 2020-12-10 Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof Pending CA3164226A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962946452P 2019-12-11 2019-12-11
US62/946,452 2019-12-11
PCT/EP2020/085623 WO2021116337A1 (en) 2019-12-11 2020-12-10 Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof

Publications (1)

Publication Number Publication Date
CA3164226A1 true CA3164226A1 (en) 2021-06-17

Family

ID=74104042

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3164226A Pending CA3164226A1 (en) 2019-12-11 2020-12-10 Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof

Country Status (9)

Country Link
US (2) US20210188990A1 (https=)
EP (1) EP4073111A1 (https=)
JP (2) JP7837867B2 (https=)
KR (1) KR20220130687A (https=)
CN (1) CN115087670B (https=)
AU (1) AU2020401755A1 (https=)
CA (1) CA3164226A1 (https=)
IL (1) IL293742A (https=)
WO (1) WO2021116337A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115677851B (zh) * 2021-07-29 2024-03-22 东莞市朋志生物科技有限公司 一种免疫阻断抗体或其抗原结合片段及其应用
CR20240246A (es) * 2021-12-20 2024-07-19 Hoffmann La Roche Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
US20250235534A1 (en) * 2022-04-13 2025-07-24 Vib Vzw An LTBR Agonist In Combination Therapy Against Cancer
IL318055A (en) 2022-07-08 2025-02-01 Viromissile Inc ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF
KR20260036556A (ko) 2023-07-07 2026-03-17 메스태그 테라퓨틱스 리미티드 결합 작제물
EP4527851A1 (en) 2023-09-22 2025-03-26 Bayer Aktiengesellschaft Bispecific antibodies binding ltbr and lrrc15
WO2025172588A1 (en) 2024-02-16 2025-08-21 Mestag Therapeutics Ltd Bispecific constructs directed against fap and ltbr
WO2025172587A1 (en) 2024-02-16 2025-08-21 Mestag Therapeutics Ltd Binding constructs
WO2025221728A2 (en) * 2024-04-15 2025-10-23 Janssen Biotech, Inc. Ltbr binding molecules and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
JP2003524018A (ja) * 2000-02-24 2003-08-12 アイトゲネーシシェ テクニシェ ホッホシューレ チューリッヒ フィブロネクチンのｅｄ‐ｂドメインに特異的な抗体、前記抗体を含む複合体、および血管形成を検出および治療するためのその使用
PL366307A1 (en) 2000-10-13 2005-01-24 Biogen, Inc. Humanized anti-lt-beta-r antibodies
CA2491480A1 (en) 2002-07-01 2004-01-08 Biogen, Inc. Humanized anti-lymphotoxin beta receptor antibodies
CA2511013A1 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
WO2004058183A2 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Lymphotoxin beta receptor agents in combination with chemotherapeutic agents
KR20060132006A (ko) * 2004-03-23 2006-12-20 비오겐 아이덱 엠에이 아이엔씨. 수용체 커플링제 및 이의 치료적 용도
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
EP1892248A1 (en) 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
MX2012002428A (es) 2009-08-27 2012-09-12 Covagen Ag Compuestos de union il-17 y usos medicos de los mismos.
HRP20241208T1 (hr) 2010-04-20 2024-11-22 Genmab A/S Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
BR112014010580B1 (pt) 2011-11-04 2021-01-12 Zymeworks, Inc. constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado
EP2638916A1 (en) * 2012-03-16 2013-09-18 Covagen AG Novel binding molecules with antitumoral activity
JP6325463B2 (ja) 2012-03-16 2018-05-16 コヴァジェン アクチェン ゲゼルシャフト 抗腫瘍活性を有する新規結合分子
WO2014170063A1 (en) 2013-04-19 2014-10-23 Covagen Ag Novel bispecific binding molecules with antitumoral activity
US20170335281A1 (en) * 2014-03-15 2017-11-23 Novartis Ag Treatment of cancer using chimeric antigen receptor
EP3341410B1 (en) * 2015-08-24 2021-06-02 Cellectis Chimeric antigen receptors with integrated controllable functions
WO2018119118A1 (en) 2016-12-20 2018-06-28 Oncomed Pharmaceuticals, Inc. Lymphotoxin-beta receptor-binding agents, targeting antibodies, and uses thereof
US20190100587A1 (en) 2017-10-02 2019-04-04 Covagen Ag IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS
CN114258400A (zh) * 2019-08-15 2022-03-29 詹森生物科技公司 用于改进的单链可变片段的材料和方法

Also Published As

Publication number Publication date
IL293742A (en) 2022-08-01
EP4073111A1 (en) 2022-10-19
JP2025111508A (ja) 2025-07-30
JP7837867B2 (ja) 2026-03-31
AU2020401755A1 (en) 2022-08-04
KR20220130687A (ko) 2022-09-27
CN115087670B (zh) 2025-10-28
US20250101123A1 (en) 2025-03-27
JP2023506750A (ja) 2023-02-20
WO2021116337A1 (en) 2021-06-17
US20210188990A1 (en) 2021-06-24
CN115087670A (zh) 2022-09-20

Similar Documents

Publication Publication Date Title
US20250101123A1 (en) Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof
KR20180030852A (ko) Flt3 및 cd3을 위한 항체 작제물
WO2022111576A1 (en) Novel conjugate molecules targeting cd39 and tgfβeta
CA3073733A1 (en) Anti-lag-3 antibodies and uses thereof
WO2022056197A1 (en) Immune targeting molecules and uses thereof
JP2023518189A (ja) デルタ鎖媒介性免疫を調節するための材料及び方法
KR20220145854A (ko) 지방산 분자와 접합된 항체 및 이의 용도
US20240124574A1 (en) Bispecific Antibodies with Charge Pairs and Uses Thereof
CA3173176A1 (en) Anti-tumor associated antigen antibodies and uses thereof
CA3244124A1 (en) Anti-mesothelin antibodies and their uses
TWI857471B (zh) 抗btla抗體及其於治療癌症之用途
WO2025221736A2 (en) Ltbr binding molecules and uses thereof
CA2963718C (en) Antigen binding molecules comprising a tnf family ligand trimer
WO2024102604A1 (en) Anti-5t4 antibodies and uses thereof
WO2024182475A2 (en) Anti-ror2 antibodies and uses thereof
CA2963718A1 (en) Antigen binding molecules comprising a tnf family ligand trimer

Legal Events

Date Code Title Description
P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20241011

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241206

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20241206

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241206

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20241211

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250319

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED

Effective date: 20250716

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250717

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT

Effective date: 20250718

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250718

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251028

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251028